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Original Article
Objectives: C-reactive protein (CRP), an inflammatory biomarker, has been widely used as a preclinical marker predictive of morbidity 
and mortality. Although many studies have reported a positive association between CRP and mortality, uncertainty still remains 
about this association in various populations, especially in rural Korea.
Methods: A total of 23 233 middle-aged participants (8862 men and 14 371 women) who were free from cardiovascular disease, can-
cer, and acute inflammation (defined by a CRP level ≥10 mg/L) were drawn from 11 rural communities in Korea between 2005 and 
2011. Blood CRP concentration was analyzed as a categorical variable (low: 0.0-0.9 mg/L; intermediate: 1.0-3.0 mg/L; high: 3.1-9.9 mg/L) 
as well as a continuous variable. Each participant’s vital status through December 2013 was confirmed by death statistics from the Na-
tional Statistical Office. Cox proportional hazard models were used to assess the independent association between CRP and mortality 
after adjusting for other risk factors. 
Results: The total quantity of observed person-years was 57 975 for men and 95 146 for women, and the number of deaths was 649 
among men and 367 among women. Compared to the low-CRP group, the adjusted hazard ratio for all-cause mortality of the inter-
mediate group was 1.17 (95% confidence interval [CI], 0.98 to 1.40) for men and 1.27 (95% CI, 1.01 to 1.61) for women, and the corre-
sponding values for the high-CRP group were 1.98 (95% CI, 1.61 to 2.42) for men and 1.41 (95% CI, 1.03 to 1.95) for women. Similar 
trends were found for CRP evaluated as a continuous variable and for cardiovascular mortality. 
Conclusions: Higher CRP concentrations were associated with higher mortality in a rural Korean population, and this association was 
more prominent in men than in women. 
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INTRODUCTION
Chronic inflammation has been considered to be an emerg-
ing risk factor for many chronic diseases, such as cancers and 
cardiovascular disease (CVD) [1-3]. C-reactive protein (CRP) is a 
widely used inflammatory marker, and reflects both acute and 
chronic inflammation status. Although many other biomarkers 
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indicate inflammation status, such as fibrinogen levels, white 
cell count, and erythrocyte sedimentation rate, CRP is the only 
established biomarker that can be used for risk assessment as 
part of the primary prevention of CVD [4,5]. Several studies 
have reported associations between CRP and the incidence of 
vascular and non-vascular disease [6,7], as well as associations 
between CRP and cause-specific and all-cause mortality [8-
11]. Recently, some articles have suggested that these associa-
tions may be affected by the presence of other risk factors for 
CVD [12-16]. It is not clear whether CRP is directly associated 
with mortality or is associated with mortality due to the pres-
ence of other risk factors, such as hypertension. 
In addition, most previous studies addressing associations 
between CRP and mortality have reported findings from West-
ern populations [7,12,17]. Although some studies have been 
carried out in East Asia, few studies have dealt with rural popu-
lations [6,11,13]. Differently distributed blood concentrations 
of CRP have been found in different ethnic groups, and the re-
lationship between mortality and CRP has been found to vary 
between rural and urban areas due to distinct lifestyle factors 
[18-20]. The role of CRP in predicting risk for CVD and mortality 
appears to be different from population to population. To the 
best of our knowledge, no previous research has assessed the 
association between CRP and all-cause mortality in a rural Ko-
rean population. Thus, we aimed to evaluate the association of 
CRP with all-cause mortality and cardiovascular mortality in 
rural regions in Korea. Additionally, we aimed to determine 
whether the association between CRP and all-cause mortality 
was modified by the presence of hypertension.
METHODS
Study Participants
We used data from the Korean Genome and Epidemiology 
Study - Cardiovascular Disease Association Study (KoGES_CA-
VAS). The aims, recruitment criteria, and baseline characteris-
tics of KoGES_CAVAS have been described in more detail else-
where [21]. In brief, a total of 28 338 community dwellers (age 
≥40 years) were recruited from 11 rural communities in Korea 
from 2005 to 2011. In eight communities, the study partici-
pants were recruited beginning in 2005, and those in the other 
three communities were recruited beginning in 2006. The fol-
low-up is ongoing, and in this study, we assessed mortality 
cases based on data from the National Statistical Office. We ex-
cluded 2346 participants with a history of stroke, angina, myo-
cardial infarction, or cancer, and then excluded 484 partici-
pants due to evidence of acute inflammation (CRP ≥10 mg/L). 
Next, we excluded 227 participants whose vital status could 
not be confirmed, as well as 1604 participants whose CRP con-
centrations were not measured. Finally, we excluded 442 par-
ticipants due to missing data in some independent variables, 
as well as two participants who died in the same month that 
they were enrolled in the study. Thus, a total of 23 233 people 
(8862 men and 14 371 women) were included in the final anal-
ysis. All participants provided written informed consent, and 
the study protocol was approved by the institutional review 
board of each institution that participated in KoGES_CAVAS. 
Data Collection
Information about demographic factors, socioeconomic sta-
tus, health behaviors, and disease history were collected using 
a standardized questionnaire. Educational status was used to 
represent socioeconomic status, and was defined as elemen-
tary school or below, middle school, high school, and universi-
ty or above. Non-smokers were defined as those who had con-
sumed less than 400 cigarettes over the course of their lifetime 
[22]. Participants who had consumed 400 or more cigarettes 
were categorized into two groups: former smokers, who ab-
stained from smoking at the time of the questionnaire, and 
current smokers, who persisted in smoking. Participants were 
divided according to their alcohol consumption as never drink-
ers, former drinkers, and current drinker. Never drinkers were 
defined as those who had never consumed an alcoholic drink 
over the course of their lifetime, for physical or other reasons. 
Former drinkers were defined as participants who abstained 
from drinking at the time of the questionnaire, while current 
drinkers were defined as those who persisted in consuming al-
cohol. Participants were classified in terms of regular exercise 
based on ‘yes’ and ‘no’ answers to the following question. “Do 
you currently engage in regular exercise strenuous enough to 
cause you to break into a sweat at least once per week?” 
Anthropometric measurements were also obtained using 
standardized methods. Body mass index (BMI) was calculated 
as weight (kg) divided by height squared (m2). Participants 
were defined into four classes based on BMI: underweight 
(BMI <18.5 kg/m2), normal (18.5≤ BMI <23.0 kg/m2), over-
weight (23.0≤ BMI <25.0 kg/m2), and obesity (BMI ≥25.0 kg/
m2), according to the World Health Organization classification 
of BMI in adult Asians [23]. Systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) were measured twice in the 
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right arm using a standardized mercury or automatic sphyg-
momanometer depending on the institution. Participants 
were seated for at least five minutes before the blood pressure 
measurements, and the mean of the two blood pressure read-
ings was recorded for data analysis. Laboratory evaluations 
were performed using blood samples obtained after partici-
pants had fasted overnight. Blood concentrations of glucose, 
total cholesterol, high-density lipoprotein (HDL) cholesterol, 
and triglycerides were measured using the enzyme method 
(ADVIA 1650 and ADVIA 1800; Siemens Healthineers, Deer-
field, IL, USA). Low-density lipoprotein (LDL) cholesterol levels 
were calculated using the Friedewald formula [24] in individu-
als with blood triglyceride levels <4.52 mmol/L. CRP was 
measured using a turbidimetric immunoassay (ADVIA 1650 
and ADVIA 1800; Siemens Healthineers). Hypertension was 
considered to be present when the SBP was at least 140 
mmHg, the DBP was at least 90 mmHg, or if hypertension was 
self-reported based on a physician’s diagnosis. Diabetes was 
defined as a fasting blood glucose level ≥7.0 mmol/L, or a 
self-reported physician’s diagnosis. Dyslipidemia was defined 
based on a total cholesterol level ≥5.957 mmol/L, an LDL 
cholesterol level ≥3.885 mmol/L, an HDL cholesterol level 
<1.036 mmol/L, a triglyceride level ≥2.260 mmol/L, or a self-
reported physician’s diagnosis. Other diseases, such as stroke, 
angina, and myocardial infarction, were defined only based on 
a self-reported physician’s diagnosis. 
The outcome of our study was mortality. To verify partici-
pants’ vital status, their records in our study were cross-
checked with death statistics from the National Statistical Of-
fice via the Korea Centers for Disease Control and Prevention 
using an anonymized form through December 2013. Cardio-
vascular mortality was evaluated according to the Internation-
al Classification of Diseases, 10th revision. Deaths caused by 
diseases in the circulatory system (I00-I99) were considered to 
be cardiovascular deaths. As the follow-up period, we used the 
period between the month in which each participant first par-
ticipated in the study and the month of death, or December 
2013 for surviving participants. 
Statistical Analysis
Gender-stratified analyses were performed. Blood CRP con-
centrations were classified into the following three groups, ac-
cording to the National Academy of Clinical Biochemistry Lab-
oratory Medicine Practice Guidelines (NACB LMPG): low (CRP 
<1.0 mg/L), intermediate (1.0≤ CRP ≤3.0 mg/L), and high 
(CRP >3.0 mg/L) [5]. To identify category-free associations, 
blood CRP concentrations were also analyzed as a continuous 
variable. Continuous variables are represented by mean and 
standard deviation (SD), or median and interquartile range for 
skewed variables (skewness > |2|). Categorical variables are 
represented as number and percentage. We used the t-test, 
analysis of variance, the Mann-Whitney test, the Kruskal-Wallis 
test, and the chi-square test for comparisons. We estimated 
hazard ratios (HRs) and 95% confidence intervals (CIs) be-
tween CRP and mortality using the Cox proportional hazard 
model. The proportional hazard assumption was assessed by 
including interactions with time as time-dependent covariates 
in our model, and no obvious violations were found (p for pro-
portional test >0.05). As adjustment variables, we selected 
age, rural region, BMI, educational status, alcohol use, smok-
ing status, regular exercise, the presence of disease (hyperten-
sion, diabetes, and dyslipidemia), SBP, DBP, and fasting con-
centrations of blood glucose, total cholesterol, triglycerides, 
and HDL cholesterol. Adjustment variables were selected 
based on previous studies [11,13,17]. We employed restricted 
cubic splines (RCSs) to evaluate the possibility of complex (i.e., 
non-linear) hazard functions [25]. In this method, we selected 
five CRP concentration values as knots based on CRP concen-
tration percentiles, tested the linear and non-linear associa-
tions between knots using a cubic function, and presented the 
integrated graph smoothly. Since the RCS could be affected by 
outliers, we excluded values lower than the 1st percentile and 
greater than the 99th percentile. An interaction term was cre-
ated between hypertension status and CRP and was added 
into the Cox proportional hazard model. Sensitivity analysis 
was performed by excluding deaths that occurred within two 
years from the month that each participant first participated 
in the study in order to rule out deaths caused by unknown 
underlying diseases. Since blood CRP concentrations were 
right-skewed, another sensitivity analysis was performed us-
ing log-transformed blood CRP concentrations. All statistical 
analyses were performed using SAS version 9.3 (SAS Institute 
Inc., Cary, NC, USA), and RCS analysis was carried out using the 
SAS LGTPHCURV9 macro [26]. The p-values <0.05 were de-
fined as indicating statistical significance. 
RESULTS
Table 1 shows the baseline characteristics of the study par-
ticipants. The overall mean age was 58.9 years (SD, 9.1 years), 
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Table 1. Baseline characteristics of participants by C-reactive protein category by gender
Variables Overall (n=8862)
C-reactive protein (mg/L)
p-value10.0-0.9 
(n=4819)
1.0-3.0 
(n=2968)
3.1-9.9 
(n=1075)
Men
Age (y) 58.9±9.1 58.1±9.1 59.4±9.2 60.6±9.0 <0.001
Follow-up period (y) 6.5±1.7 6.6±1.6 6.6±1.7 6.4±1.8 0.10
Systolic blood pressure (mmHg) 127.9±17.1 126.7±16.5 129.3±17.6 129.5±17.4 <0.001
Diastolic blood pressure (mmHg) 81.5±10.7 81.1±10.6 82.1±10.9 81.6±10.6 <0.001
Fasting blood glucose (mmol/L) 5.33 [4.94, 5.83] 5.27 [4.94, 5.77] 5.38 [4.94, 5.99] 5.33 [4.94, 5.94] <0.001
Total cholesterol (mmol/L) 5.03±0.93 4.99±0.89 5.11±0.97 5.00±0.96 <0.001
Triglycerides (mmol/L) 1.51 [1.05, 2.27] 1.44 [1.02, 2.12] 1.68 [1.15, 2.53] 1.47 [1.02, 2.19] <0.001
HDL cholesterol (mmol/L) 1.14±0.30 1.17±0.31 1.11±0.28 1.10±0.29 <0.001
C-reactive protein (mg/L) 0.89 [0.47, 1.81] 0.50 [0.32, 0.71] 1.59 [1.24, 2.10] 4.57 [3.66, 6.02] <0.001
Body mass index (kg/m2) <0.001
<18.5 219 (2.5) 132 (2.7) 50 (1.7) 37 (3.4)
18.5-22.9 2955 (33.3) 1788 (37.1) 843 (28.4) 324 (30.1)
23.0-24.9 2358 (27.3) 1315 (28.1) 749 (25.7) 294 (28.3)
≥25.0 3330 (34.8) 1584 (32.5) 1326 (38.5) 420 (33.9)
Education <0.001
≤Elementary school 3873 (43.7) 1981 (41.1) 1366 (46.0) 526 (48.9)
Middle school 1864 (21.0) 1003 (20.8) 616 (20.8) 245 (22.8)
High school 2292 (25.9) 1282 (26.6) 769 (48.0) 241 (22.4)
≥College 833 (9.4) 553 (11.5) 217 (12.4) 63 (5.9)
Smoking <0.001
Never 2597 (29.3) 1567 (32.5) 762 (25.7) 268 (24.9)
Former 3121 (35.2) 1663 (34.5) 1080 (36.4) 378 (35.2)
Current 3144 (35.5) 1589 (33.0) 1126 (37.9) 429 (39.9)
Alcohol use <0.001
Never 2041 (23.0) 1157 (24.0) 638 (21.5) 246 (22.9)
Former 962 (10.9) 451 (9.4) 350 (11.8) 161 (15.0)
Current 5859 (66.1) 3211 (66.6) 1980 (66.7) 668 (62.1)
Regular physical activity <0.001
No 6098 (68.8) 3249 (67.4) 2079 (70.0) 770 (71.6)
Yes 2764 (31.2) 1570 (32.6) 889 (30.0) 305 (28.4)
Presence of hypertension <0.001
No 4796 (54.1) 2798 (58.1) 1458 (49.1) 540 (50.2)
Yes 4066 (45.9) 2021 (41.9) 1510 (50.9) 535 (49.8)
Presence of diabetes <0.001
No 7659 (86.4) 4260 (88.4) 2491 (83.9) 908 (84.5)
Yes 1203 (13.6) 559 (11.6) 477 (16.1) 167 (15.5)
Presence of dyslipidemia <0.001
No 3434 (38.8) 2065 (42.9) 967 (32.6) 402 (37.4)
Yes 5428 (61.3) 2754 (57.1) 2001 (67.4) 673 (62.6)
All-cause mortality <0.001
No 8213 (92.7) 4546 (94.3) 2743 (92.4) 924 (86.0)
Yes 649 (7.3) 273 (5.7) 225 (7.6) 151 (14.0)
Cardiovascular mortality <0.001
No 8775 (99.0) 4780 (99.2) 2938 (99.0) 1057 (98.3)
Yes 87 (1.0) 39 (0.8) 30 (1.0) 18 (1.7)
( Continued to the next page)
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Table 1. Continued from the previous page
Variables Overall (n=14 371)
C-reactive protein (mg/L)
p-value10.0-0.9 
(n=9221)
1.0-3.0 
(n=3858)
3.1-9.9 
(n=1292)
Women
Age (y) 57.8±9.4 56.8±9.5 59.3±9.0 59.6±9.1 <0.001
Follow-up period (y) 6.6±1.5 6.6±1.5 6.6±1.6 6.7±1.5 0.03
Systolic blood pressure (mmHg) 125.2±18.2 123.7±18.0 127.6±18.2 128.5±18.5 <0.001
Diastolic blood pressure (mmHg) 78.4±11.1 77.7±11.0 79.5±11.2 80.2±11.2 <0.001
Fasting glucose (mmol/L) 5.11 [4.77, 5.55] 5.05 [4.72, 5.44] 5.22 [4.83, 5.72] 5.22 [4.83, 5.77] <0.001
Total cholesterol (mmol/L) 5.30±0.96 5.23±0.93 5.40±0.99 5.47±1.03 <0.001
Triglycerides (mmol/L) 1.36 [0.97, 1.93] 1.27 [0.93, 1.77] 1.53 [1.08, 2.18] 1.50 [1.07, 2.18] <0.001
HDL cholesterol (mmol/L) 1.20±0.28 1.23±0.28 1.16±0.26 1.14±0.27 <0.001
C-reactive protein (mg/L) 0.68 [0.36, 1.39] 0.44 [0.27, 0.65] 1.52 [1.22, 2.03] 4.52 [3.59, 6.10] <0.001
Body mass index (kg/m2) <0.001
<18.5 243 (1.7) 195 (2.1) 34 (0.9) 14 (1.1)
18.5-22.9 4473 (31.1) 3380 (36.7) 847 (22.0) 246 (19.0)
23.0-24.9 3680 (26.0) 2505 (27.8) 901 (23.6) 274 (21.4)
≥25.0 5975 (31.2) 3141 (27.5) 2076 (36.0) 758 (38.5)
Education <0.001
≤Elementary school 9504 (66.1) 5787 (62.8) 2782 (72.1) 935 (72.4)
Middle school 2183 (15.2) 1478 (16.0) 529 (13.7) 176 (13.6)
High school 2199 (15.3) 1586 (17.2) 461 (11.9) 152 (11.8)
≥College 485 (3.4) 370 (4.0) 86 (2.2) 29 (2.2)
Smoking <0.001
Never 13 849 (96.4) 8937 (96.9) 3679 (95.4) 1233 (95.4)
Former 171 (1.2) 85 (0.9) 64 (1.7) 22 (1.7)
Current 351 (2.4) 199 (2.2) 115 (3.0) 37 (2.9)
Alcohol use 0.003
Never 9824 (68.4) 6251 (67.8) 2650 (68.7) 923 (71.4)
Former 495 (3.4) 296 (3.2) 145 (3.8) 54 (4.2)
Current 4052 (28.2) 2674 (29.0) 1063 (27.6) 315 (24.4)
Regular physical activity 0.02
No 9925 (69.1) 6320 (68.5) 2669 (69.2) 936 (72.4)
Yes 4446 (30.9) 2901 (31.5) 1189 (30.8) 356 (27.6)
Presence of hypertension <0.001
No 8321 (57.9) 5783 (62.7) 1902 (49.3) 636 (49.2)
Yes 6050 (42.1) 3438 (37.3) 1956 (50.7) 656 (50.8)
Presence of diabetes <0.001
No 12 975 (90.3) 8574 (93.0) 3296 (85.4) 1105 (85.5)
Yes 1396 (9.7) 647 (7.0) 562 (14.6) 187 (14.5)
Presence of dyslipidemia <0.001
No 6148 (42.8) 4412 (47.8) 1339 (34.7) 397 (30.7)
Yes 8223 (57.2) 4809 (52.2) 2519 (65.3) 895 (69.3)
All-cause mortality <0.001
No 14 004 (97.4) 9032 (98.0) 3731 (96.7) 1241 (96.1)
Yes 367 (2.6) 189 (2.0) 127 (3.3) 51 (3.9)
Cardiovascular mortality <0.001
No 14 293 (99.5) 9181 (99.6) 3831 (99.3) 1281 (99.1)
Yes 78 (0.5) 40 (0.4) 27 (0.7) 11 (0.9)
Values are presented as number (%), mean±SD, or median [IQR]. 
HDL, high-density lipoprotein; SD, standard deviation; IQR, interquartile range. 
1p-values were derived from analysis of variance, the Kruskal-Wallis test, or the chi-square test.
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women, while the intermediate-CRP group showed a signifi-
cant adjusted HR only for women: the HR was 1.17 (95% CI, 
0.98 to 1.40) for men and 1.27 (95% CI, 1.01 to 1.61) for wom-
en. The results of the Cox regression analysis of CRP levels on 
cardiovascular mortality were similar to those between CRP 
levels and all-cause mortality, although the relationship was 
only significant for continuous CRP concentrations in men. In 
the sensitivity analysis, in which deaths occurring within two 
years from the beginning of study participation were exclud-
ed, the HR was attenuated, but the tendency was consistent. 
When blood CRP concentrations were used as a continuous 
variable, the adjusted HR for CRP and all-cause mortality for 
men was 1.10 (95% CI, 1.05 to 1.14) and 1.05 (95% CI, 0.98 to 
1.12) for women. When analyses were performed using log-
transformed CRP values, the HR likewise showed a consistent 
tendency. The adjusted HR between CRP and all-cause mortal-
ity for men was 1.26 (95% CI, 1.16 to 1.36) and 1.16 (95% CI, 
1.04 to 1.29) for women. The sensitivity analysis between CRP 
and cardiovascular mortality showed a consistent tendency 
(data not shown). 
and the mean duration of follow-up was 6.5 years (SD, 1.7 
years) for men. The overall mean age was 57.8 years (SD, 9.4 
years), and the mean duration of follow-up was 6.6 years (SD, 
1.5 years) for women. Most variables showed significant differ-
ences in their values among the CRP concentration groups. 
Overall, men participants had a higher median CRP concentra-
tion than women participants (0.89 mg/L for men, 0.68 mg/L 
for women). In order to evaluate selection bias, we compared 
the baseline characteristics between study participants and 
non-participants, and did not find a statistically significant dif-
ference in CRP concentration (Supplemental Table 1). 
Table 2 shows the result of the Cox regression analysis of 
CRP on all-cause and cardiovascular mortality per 1000 per-
son-years. The high-CRP group showed the highest mortality 
rate. During the follow-up period, 649 men participants and 
367 women participants died. Adjusting for our adjustment 
variables attenuated the strength of the association. Com-
pared to the low-CRP group, the high-CRP group showed a 
significant adjusted HR for both gender: the HR was 1.98 (95% 
CI, 1.61 to 2.42) for men and 1.41 (95% CI, 1.03 to 1.95) for 
Table 2. Cox regression analysis of C-reactive protein on all-cause and cardiovascular mortality
C-reactive protein (mg/L) n No. of deaths Mortality per 1000 person-years Unadjusted Age-adjusted Multi-adjusted
1 
All-cause mortality
Men
Low (0.0-0.9) 4819 273 8.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
Intermediate (1.0-3.0) 2968 225 11.6 1.34 (1.12, 1.60) 1.19 (1.00, 1.42) 1.17 (0.98, 1.40)
High (3.1-9.9) 1075 151 21.8 2.53 (2.07, 3.08) 2.07 (1.70, 2.53) 1.98 (1.61, 2.42)
Continuous (per 1.0 mg/L) 8862 649 11.2 1.19 (1.15, 1.23) 1.14 (1.10, 1.18) 1.13 (1.09, 1.17)
Women
Low (0.0-0.9) 9221 189 3.1 1.00 (reference) 1.00 (reference) 1.00 (reference)
Intermediate (1.0-3.0) 3858 127 5.0 1.60 (1.28, 2.00) 1.31 (1.05, 1.65) 1.27 (1.01, 1.61)
High (3.1-9.9) 1292 51 5.9 1.88 (1.38, 2.56) 1.46 (1.07, 1.99) 1.41 (1.03, 1.95)
Continuous (per 1.0 mg/L) 14 371 367 3.9 1.13 (1.07, 1.19) 1.07 (1.10, 1.14) 1.06 (1.00, 1.13)
Cardiovascular mortality
Men
Low (0.0-0.9) 4819 39 1.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
Intermediate (1.0-3.0) 2968 30 1.5 1.25 (0.78, 2.01) 1.11 (0.69, 1.80) 1.04 (0.64, 1.69)
High (3.1-9.9) 1075 18 2.6 2.11 (1.21, 3.68) 1.74 (0.99, 3.04) 1.64 (0.92, 2.91)
Continuous (per 1.0 mg/L) 8862 87 1.5 1.19 (1.08, 1.31) 1.15 (1.04, 1.26) 1.14 (1.03, 1.26)
Women
Low (0.0-0.9) 9221 40 0.7 1.00 (reference) 1.00 (reference) 1.00 (reference)
Intermediate (1.0-3.0) 3858 27 1.1 1.60 (0.98, 2.60) 1.27 (0.78, 2.07) 1.32 (0.80, 2.19)
High (3.1-9.9) 1292 11 1.3 1.80 (0.97, 3.70) 1.38 (0.71, 2.69) 1.53 (0.76, 3.06)
Continuous (per 1.0 mg/L) 14 371 78 0.8 1.16 (1.04, 1.29) 1.09 (0.97, 1.22) 1.11 (0.98, 1.25)
Values are presented as hazard ratio (95% confidence interval).
1Adjusted for age, rural region, body mass index, educational status, alcohol use, smoking status, regular exercise, presence of disease (hypertension, diabetes, and dyslipid-
emia), systolic blood pressure, diastolic blood pressure, fasting blood glucose, and concentrations of total cholesterol, triglycerides, and high-density lipoprotein cholesterol. 
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In Figure 1, the RCS shows a significant non-linear pattern 
between blood CRP concentrations and all-cause mortality for 
men (p-value for the non-linear relation of 0.048; p-value for 
the linear relation lower than 0.001), while a significant linear 
pattern was found for women (p-value for the non-linear rela-
tion of 0.267; p-value for the linear relation of 0.013). The RCS 
between blood CRP concentrations and cardiovascular mor-
tality did not show a significant association. Table 3 shows the 
Figure 1. The associations of CRP concentrations with HRs for all-cause mortality (A, C) and cardiovascular mortality (B, D). Knots 
were set at the 5th, 25th, 75th, and 95th percentiles, and the plot was truncated at the 1st and 99th percentiles. The median CRP 
level was used as the reference. HRs were adjusted for age, rural region, body mass index, educational status, alcohol use, smok-
ing status, regular exercise, the presence of disease (hypertension, diabetes, and dyslipidemia), systolic blood pressure, diastolic 
blood pressure, fasting blood glucose, and concentrations of total cholesterol, triglycerides, and high-density lipoprotein choles-
terol. In (A), the p-value for the non-linear relation was 0.048, so we show the spline model. In (C), the p-value for the non-linear 
relation was 0.267, but the p-value for the linear relation was 0.013, so we show the linear model. In (B) and  (D), neither the linear 
nor the non-linear relation was significant (all p-values >0.05). In these cases, we show the linear model. CRP, C-reactive protein; 
HR, harzard ratio; CI, confidence interval.
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interaction of hypertension with this relationship in both gen-
der. All interaction terms were insignificant. When CRP was 
analyzed as a categorical variable (Supplemental Table 2), only 
the interaction term between CRP and hypertension for all-
cause mortality was significant in a comparison of the low-
CRP and high-CRP groups in women.
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DISCUSSION 
We observed a non-linear association between blood CRP 
concentrations and all-cause mortality in a rural Korean men 
population, and a linear association in a rural Korean women 
population. Many observational studies have reported such 
associations, but most of them analyzed these associations us-
ing predetermined CRP risk groups, or based on the p-for-
trend for fractile-based groups [12,27,28]. One meta-analysis 
showed a log-linear association, but its participants were 
mostly white [7]. In Figure 1A in this study, the HR is shown to 
have rapidly increased as CRP concentration increased from 1 
mg/L to 3 mg/L. However, only a small HR increase was found 
for CRP levels >3 mg/L. Based on these results, we suggest 
that a more accurate risk grouping for men in Korea is needed 
within the intermediate risk group [20,29]. Originally, the 
NACB LMPG risk groups for CRP were determined by US popu-
lation tertiles, but some studies in East Asia have reported 
lower average CRP concentrations than those observed in 
Western countries [30-32]. In contrast, as shown in Figure 1B, 
only a linear association was found between CRP concentra-
tions and all-cause mortality in women. The estimated HR be-
tween CRP and all-cause mortality for women was lower than 
that for men in our study, although both relationships were 
significant. This discrepancy may be due to gender differences 
in CRP concentrations and mortality [12]. In other studies that 
showed significant associations between CRP and mortality 
for men, significant associations were rarely found in women 
[11,27]. Due to this gender-based discrepancy, further evalua-
tion will be needed regarding the different association pat-
terns observed between CRP and mortality according to gen-
der. Meanwhile, associations between CRP and cardiovascular 
mortality were not found to be significant (Figure 1). This find-
ing is not consistent with our results presented in Table 2, in 
which CRP concentrations were used as a continuous variable. 
This discrepancy within our study may be due to methodolog-
ical differences. Since we excluded outliers for the RCS analy-
sis, the results obtained using this method were more attenu-
ated than those presented in Table 2. Therefore, we were not 
able to determine whether a significant association was pres-
ent between CRP and cardiovascular mortality. The life expec-
tancy of Koreans was 78.5 years for mens and 85.1 for womens 
in 2013 [33]. Considering the average age of our study partici-
pants and the duration of follow-up, we most likely did not in-
clude enough cases of cardiovascular mortality. In addition, 
the HR for cardiovascular mortality in women increased after 
adjustment (Table 2). However, the results were still insignifi-
cant, and the adjusted HR was attenuated in comparison with 
the unadjusted HR, so this may not change the interpretation 
of our results.
Since this was the first study regarding association between 
CRP and mortality to be performed in Korean rural communi-
Table 3.  Cox regression analysis of CRP on all-cause and cardiovascular mortality according to the presence of hypertension
CRP (mg/L) n Median CRP (mg/L) No, of of death Mortality per 1000 person-years
Multi-adjusted1 
HR (95% CI) p for interaction
All-cause mortality
Men
Hypertension ( -) 4796 0.79 323 10.4 1.15 (1.09, 1.20) -
Hypertension (+) 4066 1.01 326 12.1 1.11 (1.05, 1.17) 0.32
Women
Hypertension (-) 8321 0.59 168 3.1 1.11 (1.02, 1.21) -
Hypertension (+) 6050 0.84 199 4.9 1.02 (0.94, 1.11) 0.11
Cardiovascular mortality
Men
Hypertension ( -) 4796 0.79 41 1.3 1.14 (0.98, 1.32) -
Hypertension (+) 4066 1.01 46 1.7 1.19 (1.04, 1.37) 0.58
Women
Hypertension (-) 8321 0.59 31 0.6 1.10 (0.88, 1.38) -
Hypertension (+) 6050 0.84 47 1.2 1.13 (0.97, 1.31) 0.83
CRP, C-reactive protein; HR, hazard ratio; CI, confidence interval.
1Adjusted for age, rural region, body mass index, educational status, alcohol use, smoking status, regular exercise, presence of disease (diabetes and dyslipidemia), systolic 
blood pressure, diastolic blood pressure, fasting blood glucose, and concentrations of total cholesterol, triglycerides, and high-density lipoprotein cholesterol. 
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ties, we compared our findings with those of previous studies 
conducted in rural areas. One such study conducted in Japan 
reported that participants within the highest tertile of CRP 
concentrations showed higher all-cause mortality (HR=2.26) 
than the lowest-tertile group in men [6]. A study conducted in 
Finland showed an insignificant association between CRP and 
all-cause mortality after adjustment for conventional CVD risk 
factors [34]. Our study results were consistent with those of 
the study performed in Japan. In addition, we compared our 
results to those of another large cohort study in Korea [11]. 
That study reported a significant association between CRP and 
all-cause mortality in men. However, our results showed high-
er CRP concentrations and mortality rates. The population of 
that study included participants who underwent health check-
ups in urban areas, and the average age of the participants 
was lower than in our study. This may have affected differenc-
es in blood CRP concentrations, but the presence of such an 
association was consistent across different populations in Ko-
rea. Generally, rural inhabitants had a lower socioeconomic 
status, less access to health services, and lived in more hazard-
ous environments than urban inhabitants [35]. Due to the dif-
ficulty of enrolling rural inhabitants, many large studies target-
ing apparently healthy people have been conducted in urban 
areas. Our study is unique in that it focused on multiple rural 
areas, showing the health landscape among a difficult-to-
study population. 
Another aim of our study was to evaluate the effect of hy-
pertension in modifying the association between blood CRP 
concentrations and mortality. However, our analysis that was 
stratified according to the presence of hypertension did not 
show a significant interaction (p for interaction >0.1), and in-
cluding hypertension as a confounder in our analyses did not 
cause the relationship between CRP and all-cause mortality to 
become insignificant (Table 2). Therefore, hypertension might 
be neither an effect modifier nor a mediator. Although a sig-
nificant interaction was found between CRP risk groups and 
all-cause mortality when CRP concentration was analyzed as a 
categorical variable (Supplemental Table 2), we were not able 
to reach a conclusion regarding effect modification due to the 
low number of deaths over an insufficient follow-up period. 
Similarly, previous studies evaluating the effect modification 
of diabetes and hypertension on the relationship between 
CRP and mortality reported insignificant results [15,16]. 
This study has some limitations. First, although we recruited 
participants from 11 rural communities in order to obtain a 
representative sample, only volunteers participated in the 
study. Therefore, selection bias may have been present be-
tween study participants and non-participants. As a result, our 
findings must be applied carefully to the entire population of 
rural Korean inhabitants. Second, we were not able to examine 
the incidence of some diseases, such as hypertension, diabe-
tes, dyslipidemia, or CVD. Not only disease presence, but dis-
ease incidence may affect the association between CRP and 
mortality. Further research with respect to disease incidence 
therefore needs to be carried out. Third, a limited approach to 
disease history was another limitation of our study. We only 
evaluated the presence of common diseases, such that the ef-
fects of other inflammatory diseases that affect CRP, such as 
rheumatoid arthritis, were not assessed. Fourth, the partici-
pants’ history of taking medications with direct effects on CRP 
concentrations was not available in our data. Angiotensin II re-
ceptor blockers, beta-blockers, and statins have been reported 
to reduce CRP concentrations [36,37]. Finally, we measured 
blood CRP concentrations only once. Repeat measurements 
would be needed to evaluate intraparticipant CRP variability. 
However, in a previous study, changes in CRP were not found 
to have a significant effect on mortality [11].  
In conclusion, blood CRP concentration showed a positive 
association with all-cause mortality and cardiovascular mor-
tality in a rural Korean population. The strength of the associa-
tion among men was greater than among women. This associ-
ation was not found to be modified by the presence of hyper-
tension. Further evaluation of the associations between CRP 
and other outcomes, such as hypertension or CVD incidence, 
is needed.  
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Supplemental Table 1. Comparison of baseline characteristics between study participants and non-participants
Variables
Study participants Non-participants
p-value1
n Mean±SD n Mean±SD
Men
   Age (y) 8862 58.9±9.1 773 58.9±9.2 0.88
   Systolic blood pressure (mm Hg) 8862 127.9±17.1 757 126.6±17.5 0.04
   Diastolic blood pressure (mm Hg) 8862 81.5±10.7 752 80.7±11.8 0.07
   Fasting blood glucose (mmol/L) 8862 5.33±0.88 768 5.33±0.94 0.60
   Total cholesterol (mmol/L) 8862 5.03±0.93 768 4.98±0.97 0.12
   Triglycerides (mmol/L) 8862 1.51±1.22 767 1.41±1.07 0.02
   HDL cholesterol (mmol/L) 8862 1.14±0.30 767 1.12±0.29 0.14
   C-reactive protein (mg/L) 8862 0.89±1.34 233 0.85±1.02 0.57
Women
   Age (y) 14 371 57.8±9.4 1502 56.3±9.1 <0.001
   Systolic blood pressure (mm Hg) 14 371 125.2±18.2 1476 124.3±18.2 0.07
   Diastolic blood pressure (mm Hg) 14 371 78.4±11.1 1466 77.2±11.2 <0.001
   Fasting blood glucose (mmol/L) 14 371 5.11±0.78 1494 5.05±0.67 <0.001
   Total cholesterol (mmol/L) 14 371 5.30±0.96 1494 5.20±0.95 <0.001
   Triglycerides (mmol/L) 14 371 1.36±0.96 1486 1.32±0.93 0.05
   HDL cholesterol (mmol/L) 14 371 1.20±0.29 1493 1.20±0.28 0.43
   C-reactive protein (mg/L) 14 371 0.68±1.03 434 0.64±1.03 0.17
Values of the concentrations of fasting glucose, triglycerides, and C-reactive protein are presented as median±IQR, while other variables are presented as mean±SD. 
HDL, high-density lipoprotein; SD, standard deviation; IQR, interquartile range. 
1p-values were derived from the t-test and the Mann-Whitney test.
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Supplemental Table 2. Cox regression analysis of CRP on all-cause and cardiovascular mortality according to the presence of 
hypertension (by CRP group)
n No. of deaths Mortality per 1000 person-years
Multi-adjusted1
HR (95% CI)
p for interaction 
(vs. low-CRP group)
All-cause mortality
Men
Low-CRP group
No hypertension 2798 138 7.6 1.00 (reference)
Hypertension 2021 135 10.1 1.10 (0.84, 1.44)
Intermediate-CRP group 0.46
No hypertension 1458 109 11.5 1.25 (0.97, 1.61)
Hypertension 1510 116 11.6 1.20 (0.90, 1.60)
High-CRP group 0.23
No hypertension 540 76 22.0 2.23 (1.28, 2.96)
Hypertension 535 75 21.7 1.92 (1.40, 2.63)
Women
Low-CRP group
No hypertension 5783 94 2.5 1.00 (reference)
Hypertension 3438 95 4.2 1.04 (0.74, 1.45)
Intermediate-CRP group 0.41
No hypertension 1902 45 3.6 1.12 (0.78, 1.61)
Hypertension 1956 82 6.3 1.42 (1.00, 2.01)
High-CRP group 0.02
No hypertension 636 29 6.9 2.06 (1.35, 3.15)
Hypertension 656 22 4.9 1.02 (0.61, 1.71)
Cardiovascular mortality
Men
Low-CRP group
No hypertension 2798 21 1.2 1.00 (reference)
Hypertension 2021 18 1.3 0.56 (0.27, 1.18)
Intermediate-CRP group 0.63
No hypertension 1458 13 1.4 0.92 (0.46, 1.86)
Hypertension 1510 17 1.7 0.66 (0.31, 1.39)
High-CRP group 0.41
No hypertension 540 7 2.0 1.26 (0.53, 3.00)
Hypertension 535 11 3.2 1.15 (0.50, 2.64)
Women
Low-CRP group
No hypertension 5783 19 0.5 1.00 (reference)
Hypertension 3438 21 0.9 0.78 (0.37, 1.62)
Intermediate-CRP group 0.34
No hypertension 1902 8 0.6 0.96 (0.42, 2.22)
Hypertension 1956 19 1.5 1.24 (0.58, 2.66)
High-CRP group 0.93
No hypertension 636 4 1.0 1.50 (0.50, 4.49)
Hypertension 656 7 1.6 1.23 (0.46, 3.31)
CRP, C-reactive protein; HR, hazard ratio; CI, confidence interval.
1Adjusted for age, rural region, body mass index, educational status, alcohol use, smoking status, regular exercise, the presence of disease (diabetes and dyslipidemia), systolic 
blood pressure, diastolic blood pressure, fasting blood glucose, and concentrations of total cholesterol, triglycerides, and high-density lipoprotein cholesterol.
